Umoja Biopharma: Funding, Investors & Team (Oct 2026)
Umoja Biopharma specializes in cutting-edge immunotherapy that involves modifying T cells in the patient's body to effectively attack cancer. The company provides adaptable treatment plans for solid tumors and blood cancers that traditionally have low response rates to existing therapies. Using their own CAR T-cell gene therapy technology, they seek to enhance patient results at different cancer stages.
Umoja Biopharma has raised $310M across 2 funding rounds on record, the most recent a Series C of $100M announced in Jan 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Umoja Biopharma Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Umoja Biopharma Funding Rounds
Umoja Biopharma raised $210M in an undisclosed round announced in Jun 2021.
3.6 years later, a Series C of $100M was announced in Jan 2025.
Umoja Biopharma Founders and Leadership Team
Contact details for the Umoja Biopharma team: 2 of 2 have an email address on file.
Start 14-day free trial →Umoja Biopharma Funding Compared to Other Biotechnology Startups
Umoja Biopharma's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Umoja Biopharma in Biotechnology and Seattle
Companies Similar to Umoja Biopharma
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Umoja Biopharma Funding FAQs
What does Umoja Biopharma do?
Umoja Biopharma specializes in cutting-edge immunotherapy that involves modifying T cells in the patient's body to effectively attack cancer. The company provides adaptable treatment plans for solid tumors and blood cancers that traditionally have low response rates to existing therapies. Using their own CAR T-cell gene therapy technology, they seek to enhance patient results at different cancer stages.
How much funding has Umoja Biopharma raised?
Umoja Biopharma has raised $310M across 2 rounds on record. The most recent is a Series C of $100M announced in Jan 2025.
When did Umoja Biopharma last raise funding?
Umoja Biopharma's most recent funding round on record is a Series C of $100M, announced in Jan 2025.
Who founded Umoja Biopharma?
FundedIQ lists Ryan Crisman (Founder) at Umoja Biopharma.
Who is the CEO of Umoja Biopharma?
Andy Scharenberg is listed as CEO at Umoja Biopharma.
Where is Umoja Biopharma headquartered?
Umoja Biopharma is based in Seattle, Washington, United States.
How many employees does Umoja Biopharma have?
Umoja Biopharma is in the 101-250 employee band.
How does Umoja Biopharma's funding compare to other Biotechnology startups?
Umoja Biopharma's latest round of $100M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Umoja Biopharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Umoja Biopharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.